Sam Jiang explains: the majority of methods for combating respiratory viruses either are effective solely against a specific virus type or merely alleviate symptoms once an individual has fallen ill.
Influenza and similar viruses spread rapidly due to the body’s deficient defenses directly at the point of infection entry – the mucous membranes of the respiratory tract.
The researchers behind this study have engineered a nanobody. This nanobody possesses one end designed to bind to viral proteins and the other to the host’s own mucosal proteins. World of Innovation News
This technology is currently not economically viable for industrial applications due to its limited scale. However, should it demonstrate efficacy in human trials, pharmaceutical companies are expected to show swift interest.
About the Author
